A meta-analysis including about 56,000 subjects showed that GLP1-RA reduced the risk of MACE by 12%, of all-cause mortality by 12%, of renal disease progression by 17%, and of HF hospitalizations by 9% [78]. Here, GLP1R is linked to kidney disorder.